Nyrada, Inc. · ASX:NYR
Nyrada — Non-Deal Roadshow (July 2020)
20 slides from Nyrada's roadshow presentation, Jul 23, 2020
Slide 1: Nyrada Roadshow Corporate Presentation
For personal use only 23 July 2020 Sydney, Australia Nyrada Roadshow Corporate Presentation Nyrada Inc. (ASX: NYR) provides to shareholders and the market generally, the attached corporate presentation for a series of virtual investor events in late July and early August 2020. The document titled, ‘
Slide 2: Forward-Looking Statements
Forward-Looking Statements For personal use only This announcement may contain forward-looking statements. You can identify these statements by the fact they use words such as “aim”, “anticipate”, “assume”, “believe”, “continue”, “could”, “estimate”, “expect”, “intend”, “may”, “plan”, “predict”, “pr
Slide 3: Improving Lives, Offering Hope
For personal use only Improving Lives, Offering Hope New Therapies for Cardiovascular & Neurological Diseases Corporate Presentation July/August 2020 James Bonnar – CEO Prof. Gary Housley – Chair, Scientific Advisory Board ASX:NYR 1
Slide 4: Important Notice & Disclaimer
Important Notice & Disclaimer For personal use only This presentation has been prepared by Nyrada Inc (NYR or the Company). It should not Although the Company believes that the expectations reflected in the forward looking be considered as an offer or invitation to subscribe for, or purchase any sha
Slide 5: Nyrada Summary
Nyrada Summary For personal use only Drug discoverer Diverse product portfolio, significant therapeutic and commercial potential, near term milestones. and early stage developer Cholesterol lowering (PCSK9 inhibitors) program to help up to 70% of patients taking statin drugs, a market worth approxim
Slide 6: Business Model & Strategy
Business Model & Strategy For personal use only Innovative Treatments Clinical Need Market Potential Strong Patent Protection First-Line / Best in Class Commercialize Early Cardiovascular Neurology Cholesterol-lowering treatment Brain injury treatment (stroke & head trauma) Value inflection point wi
Slide 7: Cholesterol and Cardiovascular Disease
Cholesterol and Cardiovascular Disease For personal use only 1 in 4 Deaths attributed to Cardiovascular Disease • Tobacco use • High blood pressure • High LDL cholesterol Benjamin EJ et al. Heart disease and stroke statistics—2019 update: a report from the American Heart Association. Circulation. 20
Slide 8: Cholesterol Problem (US)
Cholesterol Problem (US) For personal use only 62.6 million 19.4 million 27.4 million Unable to achieve US adults with elevated Total US adults with LDL-C target despite LDL-C are taking a statin elevated LDL-C taking statin therapy Wong ND et al. Prevalence of the American College of Cardiology/Ame
Slide 9: Current Treatment Options
Current Treatment Options For personal use only Low cost generic statins available Effective, combined with statin US$16 for 100 pills Suboptimal efficacy Expensive US$5,800 per year Side effects Inconvenient US$900M global PCSK9 Inhibitor market in 2019 US$19B global cholesterol-lowering drugs mark
Slide 10: Nyrada Cholesterol-Lowering Solution
Nyrada Cholesterol-Lowering Solution For personal use only NYX-PSCK9i binds to PCSK9 Blocks action of PCSK9 on cholesterol receptor High PCSK9 = Small molecule PCSK9 inhibitor high LDL cholesterol overcomes longstanding challenge of an oral PCSK9 treatment 8
Slide 11: What is Unique?
What is Unique? For personal use only Single pill Convenient Cost- treatment for patient effective 9
Slide 12: NYX-PCSK9i Compared to Repatha® and Praluent®
NYX-PCSK9i Compared to Repatha® and Praluent® For personal use only Nyrada NYX-PCSK9i shows equivalency to Repatha® and Praluent® in human white blood cells Confirmed with/without a statin, supporting NYX-PCSK9i use alone or in combination with statin - Mevastatin + Mevastatin % LDLR retention p-val
Slide 13: Brain Injury Problem
Brain Injury Problem For personal use only Each year in the US: Neurology / physical rehabilitation only existing - High mortality - 2.8 million people sustain therapies - Severe life-long disability a traumatic brain injury (TBI) - One drug class for stroke - High ongoing healthcare (Suitable for l
Slide 14: Nyrada Brain Injury Solution
Nyrada Brain Injury Solution For personal use only Treatment for secondary brain injury following Stroke or TBI - Prevent cell death - Attenuate damaged brain volume - Improve survivability, limit disability, improve quality of life Primary Secondary Disability Injury Injury Level Hours Days Weeks M
Slide 15: Brain Injury Drug Market (US)
Brain Injury Drug Market (US) For personal use only Hospital admissions each year / patients who present <12hr Traumatic Brain Injury 210,000 (Moderate / Severe) 700,000 patients Annual US market size for brain injury combined (approx.) Stroke 490,000 US$20B global severe TBI treatment market in 202
Slide 16: Preclinical Pharmacokinetic Rat Study
Preclinical Pharmacokinetic Rat Study For personal use only • Lead drug candidates maintained at therapeutic levels in the brain in PK rat study (intravenous dosing) • Demonstrates delivery via preferred route for patients suffering from stroke and moderate-severe TBI with desired PK profiles for cl
Slide 17: Program Status
Program Status For personal use only First-in-human studies (Phase I) Proof-of-concept Lead optimisation well established advanced - Cholesterol-lowering Drug: late-2021 - Brain Injury Drug: mid-2022 15
Slide 18: Board of Directors
For personal use only Board of Directors 16
Slide 19: Key Metrics & News Flow
Key Metrics & News Flow For personal use only Market capitalisation H2 H1 H2 H1 $21M 2020 2021 2021 2022 (as at 22 July 2020) Share price Clinical candidate selection for $0.19 cholesterol program: (as at 22 July 2020) Clinical candidate selection for CDIs free float 76,072,869 neuroprotectant progr
Slide 20: Discover More & Follow Us
Discover More & Follow Us For personal use only Neuroprotection Cholesterol-Lowering Recent PCSK9i Animation Animation Publication @nyrada_inc @nyrada_inc www.nyrada.com 18